Pfizer’s Latest Acquisition Strengthens The Case For PFE Stock

This article was originally published on ValueWalk

Pfizer dividend history

Pfizer is merging with Seagen in a $43 billion acquisition. Seagen was a sought-after target and Pfizer is succeeding where Merck failed, but it paid a premium to do so. Pfizer is expecting the acquisition to add $10 billion in revenue by 2030; early indications suggest analysts are less convinced. If Pfizer is right, this […]